Bank of America Has Lowered Expectations for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price target lowered by Bank of America from $55.00 to $49.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s price objective points to a potential upside of 80.21% from the company’s current price.

A number of other research firms have also recently weighed in on ASTH. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus lowered their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Truist Financial lowered their target price on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.83.

Astrana Health Stock Up 1.5 %

NASDAQ:ASTH opened at $27.19 on Tuesday. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The stock has a market capitalization of $1.53 billion, a P/E ratio of 20.92, a P/E/G ratio of 1.37 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The company’s 50-day simple moving average is $34.57 and its 200-day simple moving average is $44.16.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. On average, equities analysts anticipate that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors have recently bought and sold shares of ASTH. State Street Corp purchased a new position in Astrana Health during the 3rd quarter worth approximately $91,966,000. Geode Capital Management LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $58,995,000. FMR LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $48,413,000. Loomis Sayles & Co. L P purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $30,251,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $25,945,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.